CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Primaquine

伯氨喹 杂质对照品Primaquine Impurities

EP24 个杂质条目24 impurity entries

本页汇总 伯氨喹 的 24 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 24 impurity reference standards of Primaquine with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 伯氨喹(Primaquine)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesPediatric formulations and challenges beyond technological development: Identification and in silico qualification of impurities in 5 mg primaquine tablets
    Journal of pharmaceutical and biomedical analysis · 2025 · Carvalho Mendes T et al.  ·  PMID 40250090  ·  DOI
  2. 杂质研究Impurity studiesDevelopment and validation of UPLC method for determination of primaquine phosphate and its impurities
    Journal of pharmaceutical and biomedical analysis · 2008 · Dongre VG et al.  ·  PMID 18029132  ·  DOI
  3. 杂质研究Impurity studiesDetermination of quinocide as impurity in primaquine tablets by capillary zone electrophoresis
    Biomedical chromatography : BMC · 2009 · Elbashir AA et al.  ·  PMID 19016231  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisBatch Synthesis of Primaquine Diphosphate Anti-Malarial Drug
    Chemistry (Weinheim an der Bergstrasse, Germany) · 2025 · Akwi FM et al.  ·  PMID 40990449  ·  DOI
  • 合成方法SynthesisMachine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity
    European journal of medicinal chemistry · 2018 · Levatić J et al.  ·  PMID 29407988  ·  DOI

伯氨喹 —— 原料药与杂质对照品Primaquine — drug substance & impurities

共 24 个条目(含原料药本体)24 items incl. the drug substance
Primaquine Impurity 1 (Primaquine EP Impurity A) (Primaquine USP Related Compound A) structure
EPA
伯氨喹杂质1 (伯氨喹EP杂质A) (伯氨喹USP相关化合物A)Primaquine Impurity 1 (Primaquine EP Impurity A) (Primaquine USP Related Compound A)
Primaquine Impurity 1 (Primaquine EP Impurity A) (Primaquine USP Related Compound A)
CAS No.525-61-1
Chemical FormulaC15H21N3O
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 19(Primaquine EP Impurity B) structure
EPB
伯氨喹杂质19(伯氨喹EP杂质B)Primaquine Impurity 19(Primaquine EP Impurity B)
Primaquine Impurity 19(Primaquine EP Impurity B)
CAS No.85-81-4
Chemical FormulaC10H8N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 7(Primaquine EP Impurity C) structure
EPC
伯氨喹杂质7(伯氨喹EP杂质C)Primaquine Impurity 7(Primaquine EP Impurity C)
Primaquine Impurity 7(Primaquine EP Impurity C)
CAS No.90-52-8
Chemical FormulaC10H10N2O
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 20(Primaquine EP Impurity D) structure
EPD
伯氨喹杂质20(伯氨喹EP杂质D)Primaquine Impurity 20(Primaquine EP Impurity D)
Primaquine Impurity 20(Primaquine EP Impurity D)
CAS No.83532-78-9
Chemical FormulaC23H23N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Diphosphate-d3 structure
—
伯氨喹 二磷酸盐-d3Primaquine Diphosphate-d3
Primaquine Diphosphate-d3
CAS No.1318852-20-8
Chemical FormulaC15H18D3N3O·2H3PO4
Purity>95%询价On request
Primaquine Diphosphate structure
—
伯氨喹 二磷酸盐Primaquine Diphosphate
Primaquine Diphosphate
CAS No.63-45-6
Chemical FormulaC15H21N3O·2H3PO4
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Monomer structure
—
伯氨喹 单体Primaquine Monomer
Primaquine Monomer
CAS No.90-34-6
Chemical FormulaC15H21N3O
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 2 structure
2
伯氨喹杂质2Primaquine Impurity 2
Primaquine Impurity 2
CAS No.1660108-75-7
Chemical FormulaC14H17N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 3 Trihydrobromide structure
3
伯氨喹杂质3 三溴化氢Primaquine Impurity 3 Trihydrobromide
Primaquine Impurity 3 Trihydrobromide
CAS No.57514-28-0
Chemical FormulaC15H21N3O2·3HBr
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 3 structure
3
伯氨喹杂质3Primaquine Impurity 3
Primaquine Impurity 3
CAS No.57695-07-5
Chemical FormulaC15H21N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 4 structure
4
伯氨喹杂质4Primaquine Impurity 4
Primaquine Impurity 4
CAS No.47136-26-5
Chemical FormulaC16H23N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 5 structure
5
伯氨喹杂质5Primaquine Impurity 5
Primaquine Impurity 5
CAS No.88563-36-4
Chemical FormulaC14H19N3O·2HI
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 6 structure
6
伯氨喹杂质6Primaquine Impurity 6
Primaquine Impurity 6
CAS No.77229-68-6
Chemical FormulaC15H18N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 8 structure
8
伯氨喹杂质8Primaquine Impurity 8
Primaquine Impurity 8
CAS No.129357-93-3
Chemical FormulaC15H19N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 9 structure
9
伯氨喹杂质9Primaquine Impurity 9
Primaquine Impurity 9
CAS No.84885-43-8
Chemical FormulaC15H16N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 10 structure
10
伯氨喹杂质10Primaquine Impurity 10
Primaquine Impurity 10
CAS No.77229-69-7
Chemical FormulaC16H20N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 11 structure
11
伯氨喹杂质11Primaquine Impurity 11
Primaquine Impurity 11
CAS No.2088410-37-9
Chemical FormulaC21H31N3O6
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 12 structure
12
伯氨喹杂质12Primaquine Impurity 12
Primaquine Impurity 12
CAS No.1185934-50-2
Chemical FormulaC17H23N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 13 structure
13
伯氨喹杂质13Primaquine Impurity 13
Primaquine Impurity 13
CAS No.148795-90-8
Chemical FormulaC30H40N6O2
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 14 structure
14
伯氨喹杂质14Primaquine Impurity 14
Primaquine Impurity 14
CAS No.52025-34-0
Chemical FormulaC7H10N2O
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 15 structure
15
伯氨喹杂质15Primaquine Impurity 15
Primaquine Impurity 15
CAS No.59353-62-7
Chemical FormulaC13H14BrNO2
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 16 structure
16
伯氨喹杂质16Primaquine Impurity 16
Primaquine Impurity 16
CAS No.6340-55-2
Chemical FormulaC11H10ClNO
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 18 structure
18
伯氨喹杂质18Primaquine Impurity 18
Primaquine Impurity 18
CAS No.2732404-25-8
Chemical FormulaC15H21N3O
Purity>95%询价On request
10mg25mg50mg100mg
Primaquine Impurity 22 structure
22
伯氨喹杂质22Primaquine Impurity 22
Primaquine Impurity 22
CAS No.77229-67-5
Chemical FormulaC17H23N3O2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

伯氨喹 —— 研究文献与合成路线Primaquine — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 伯氨喹 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Primaquine. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Development and validation of UPLC method for determination of primaquine phosphate and its impurities
    Dongre VG, Karmuse PP, Rao PP, et al. · Journal of pharmaceutical and biomedical analysis · 2008 · 被引 25cited 25
  2. Determination of quinocide as impurity in primaquine tablets by capillary zone electrophoresis
    Elbashir AA, Saad B, Ali AS, et al. · Biomedical chromatography : BMC · 2009 · 被引 14cited 14
  3. Biodegradable microspheres. 17. Lysosomal degradation of primaquine-peptide spacer arms
    Borissova R, Stjärnkvist P, Karlsson MO, et al. · Journal of pharmaceutical sciences · 1995 · 被引 11cited 11
  4. Enantioselective analysis of primaquine and its impurity quinocide by capillary electrophoresis
    Elbashir AA, Saad B, Ali AS, et al. · Biomedical chromatography : BMC · 2009 · 被引 6cited 6
  5. Effects of an NADPH-generating system on primaquine degradation by hamster liver fractions
    Abu-El-Haj S, Allahyari R, Chavez E, et al. · Xenobiotica; the fate of foreign compounds in biological systems · 1988 · 被引 2cited 2
  6. Spectrophotometric determination of primaquine phosphate in pharmaceutical preparations
    Abou Ouf AA, Hassan SM, Metwally ME · The Analyst · 1980 · 被引 1cited 1

合成路线文献Synthetic-route papers

  1. Batch Synthesis of Primaquine Diphosphate Anti-Malarial Drug
    Akwi FM, Swartbooi S, Watts P · Chemistry (Weinheim an der Bergstrasse, Germany) · 2025
  2. Design, Synthesis and in vitro Evaluation of Primaquine and Diaminoquinazoline Hybrid Molecules Against the Malaria Parasite
    Kore M, Rao AG, Acharya D, et al. · Chemistry, an Asian journal · 2025
  3. Synthesis, Biological Activity and In Silico Pharmacokinetic Prediction of a New 2-Thioxo-Imidazoldidin-4-One of Primaquine
    Pereira M, Caljon G, Gouveia MJ, et al. · Pharmaceuticals (Basel, Switzerland) · 2021

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

伯氨喹 杂质谱研究要点Primaquine — impurity profiling notes

下面这些是拿到 伯氨喹 的 24 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 24 impurity entries for Primaquine, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances